Skip to main content

Financial News

  • WBA executives bullish on new year's promise following strong 2017

    DEERFIELD, Ill. — Walgreens Boots Alliance on Wednesday exceeded analyst expectations with results that came in slighlty north of the company's year-end projections thanks, in part, to the company's commitment to a fluid go-to-market strategy that is constantly evaluating customer behavior.

  • Supervalu expands wholesale reach through Associated Grocers of Florida acquisition

     MINNEAPOLIS — Supervalu on Wednesday announced its acquisition of Associated Grocers of Florida in a transaction valued at approximately $180 million.

  • The Jean Coutu Group posts 6.1% in Q2 revenue gains

    VARENNES, Quebec — The Jean Coutu Group on Thursday reported revenue gains of 6.1% to $596.8 million. Jean Coutu attributed the growth to strong overall market growth that overcame the deflationary impact associated with increased generic dispensing.

  • Former Walgreens EVP named Rite Aid president, COO

    CAMP HILL, Pa. — Rite Aid on Thursday named Kermit Crawford president and COO. Crawford, prior to serving as a retail and healthcare adviser and consultant for New York City-based Sycamore Partners, enjoyed a long career with Walgreens, most recently as EVP and president of pharmacy health and wellness.

  • AARP highlights rising specialty prices as FDA looks to tackle development costs, speed

    The price of drugs — particularly specialty drugs — is the perennial issue plaguing both patients and the companies that make them, as the cost of making a drug, estimated at around $2.6 billion with an average time of 10-15 years, will be factored into the cost of a treatment. Recently, though, patient advocates and regulators have begun acknowledging a need for something to be done about this trend.

  • Kroger Q2 sales up 3.9% to $27.6 billion

    CINCINNATI — Kroger on Friday reported net earnings of $353 million, or $0.39 per diluted share, and identical supermarket sales growth, without fuel, of 0.7% in the second quarter of 2017, which ended Aug. 12.

  • Gilead to acquire Kite Pharma

    FOSTER CITY and SANTA MONICA, Calif. — In a deal estimated at roughly $11.9 billion, Gilead Sciences will be acquiring leading cell therapy company Kite Pharma for $180 per share, the companies announced last week. Among the potential treatments Gilead will acquire is Kite’s most advanced therapy candidate, axicaabtagene ciloleucel (axi-cel), a cancer-fighting therapy expected to be the first to market to treat refractory aggressive non-Hodgkin lymphoma, with a decision date of Nov. 29.

  • Turnaround efforts continue to generate 'positive momentum,' Fred's says

    MEMPHIS, Tenn. — Fred’s on Friday posted a sales decline of 4.2% to $153 million for the four-week fiscal month ended Aug. 26. The decrease in total sales is related primarily to the closure of 39 underperforming stores in the first quarter, the company reported.

X
This ad will auto-close in 10 seconds